NasdaqCM - Nasdaq Real Time Price USD

Radiopharm Theranostics Limited (RADX)

4.0500

-0.1400

(-3.34%)

At close: April 23 at 4:00:00 PM EDT

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, favorable biodistribution and low uptake in non-target organs, except for the bladder and kidney as expectedTreatment with 177Lu-RAD202 results in a relevant tumor volume reduction and survival benefit, further pronounced with fractionated therapy vs single-dose treatment.These data further support the rationale for the ongoing Phase I therapeutic trial with

GlobeNewswire last month

RADX
-3.34%
RDPTF
Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. last month

RADX
-3.34%
RDPTF
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All brain metastases, regardless of whether they were previously treated with radiation and the tumor of origin, were detected with RAD101, demonstrating a high tumor-to-background ratio.A Phase 2b imaging study to evaluate the diagnostic performance of RAD 101 in individuals with suspected recurrent brain metastases is currently recruiting in

GlobeNewswire 2 months ago

RADX
-3.34%
RDPTF
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus shareholding in Radiopharm increases to 12.16% following the placementThe funds raised will be applied to the development of Radiopharm’s clinical pipeline SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD; NASDAQ:RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceut

GlobeNewswire 3 months ago

RADX
-3.34%
RDPTF
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon meeting clinical milestone targets SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to

GlobeNewswire 3 months ago

RADX
-3.34%
RDPTF
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumorsTen HER2-positive breast cancer patients previously dosed in a Phase 1 diagnostic study demonstrated the safety and biodistribution of 177Lu-RAD202, validating its potential for

GlobeNewswire 4 months ago

RADX
-3.34%
RDPTF
Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No associated capital raisingModest admin & financial compliance overheads SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that American Depositary Shares (“ADSs”) rep

GlobeNewswire 4 months ago

RADX
-3.34%
RDPTF

Performance Overview

Return	RADX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-9.80%	-2.34%
1-Year	-27.68%	+3.71%
3-Year	-27.68%	+6.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Radiopharm Theranostics Limited (RADX)

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Performance Overview